InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (12 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
12
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Eisele Jeffrey, Vice-Président Exécutif. Insider active across 2 companies, notably Apellis Pharmaceuticals, Inc.. Aggregated, 21 reports have been logged. Breakdown: 0 buy · 12 sells. Total volume traded: €1.3m. Activity tracked since 22 December 2021. The latest transaction was disclosed on 29 January 2025 (Cession). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Eisele Jeffrey
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations21 total
278 shares@ US$29.52360.6% of flowCommon StockSEC:0001127602-25-002379:0
1,291 shares@ US$30.42552.7% of flowCommon StockSEC:0001127602-25-001835:0
264 shares@ US$28.70210.5% of flowCommon StockSEC:0001127602-25-001193:0
63 shares@ US$33.090.1% of flowCommon StockSEC:0001127602-24-030106:0
279 shares@ US$64.13821.2% of flowCommon StockSEC:0001127602-24-002738:0
7,378 shares@ US$63.6931.0% of flowCommon StockSEC:0001127602-24-002012:0
1,607 shares@ US$64.9966.9% of flowCommon StockSEC:0001127602-24-001943:0
5,207 shares@ US$65.5822.5% of flowCommon StockSEC:0001127602-24-001603:0
19,508 shares0Common StockSEC:0001127602-24-001380:0
68 shares@ US$57.86090.3% of flowCommon StockSEC:0001127602-23-030552:0
1,646 shares@ US$68.767.7% of flowCommon StockSEC:0001127602-23-007327:0
9,886 shares0Common StockSEC:0000899243-23-005787:0
883 shares@ US$52.763.1% of flowCommon StockSEC:0001127602-23-002753:0
367 shares@ US$52.771.3% of flowCommon StockSEC:0001127602-23-002682:0
4,479 shares@ US$51.5815.2% of flowCommon StockSEC:0001127602-23-002172:0
2,033 shares@ US$52.057.0% of flowCommon StockSEC:0001127602-23-002128:0
22,580 shares0Common StockSEC:0001127602-23-001496:0
1,250 shares0Common StockSEC:0001127602-22-028239:0
434 shares@ US$38.5979.9% of flowCommon StockSEC:0001127602-22-002814:0
26,051 shares0Common StockSEC:0001127602-22-002061:0
89 shares@ US$47.8220.1% of flowCommon StockSEC:0001127602-21-031867:0
21 of 21 declarations
About Eisele Jeffrey
Eisele Jeffrey is Executive Vice President and Chief Development Officer at Apellis Pharmaceuticals, Inc. The 21 filings recorded cover the period from 2021-12-23 to 2025-01-30, and the sampled recent filings show sales of EUR 1278956, with no purchases reported.
